Несмотря на значительные достижения в разработке эффективных средств терапии, многочисленные исследования свидетельствуют о недостаточном уровне контроля БА, приводящего к снижению качества жизни пациентов, а также высокому риску обострений заболевания. Основным терапевтическим подходом, направленным на достижение контроля и снижение ущерба от заболевания, является противовоспалительная терапия, основу которой составляют современные препараты ингаляционных глюкокортикостероидов (ИГКС), при необходимости дополняемые длительно действующими β-2-адреномиметиками (ДДБА).
http://ginasthma.org/2016-gina-report-globalstrategy-for-asthma-management-and-prevention.http://ginasthma.org/2016-gina-report-globalstrategy-for-asthma-management-and-prevention
Cates CJ, Karner C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database Syst Rev, 2013, 4: CD007313.
Kew KM, Karner C, Mindus SM, Ferrara G. Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children. Cochrane Database Syst Rev, 2013 12: CD009019.
Patel M, Pilcher J, Pritchard A, et al. Efficacy and safety of maintenance and reliever combination budesonide/formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet Respir Med, 2013, 1: 32-42.
Bateman ED, Harrison TW, Quirce S et al. Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. Respir Res, 2011, 12: 38.
Herland K, Akselsen JP, Skjonsberg OH et al. How representative are clinical study patients with asthmaor COPD for a larger “real life” population of patientswith obstructive lung disease? Respir Med, 2005, 99: 11-19.
Price D, Brusselle G, Roche N, Freeman D, Chisholm A. Real-world research and its importance in respiratory medicine. Breathe, 2015, 11(1): 26-38.
Aubier M, Buhl R, Ekstrom T, Ostinelli J et al. Comparison of two twice-daily doses of budesonide/formoterol maintenance and reliever therapy. Eur Respir J, 2010, 36: 524-530.
Zhong N, Lin J, Mehta P et al. Real-life effectiveness of budesonide/formoterol maintenance and reliever therapy in asthma patients across Asia: SMARTASIA study. BMC Pulmonary Medicine, 2013, 13: 22.
Ställberg B, Naya I, Ekelund J, Eckerwall G. Real-life use of budesonide/formoterol in clinical practice: a 12-month follow-up assessment in a multi-national study of asthma patients established on single-inhaler maintenance and reliever therapy. International Journal of Clinical Pharmacology and Therapeutics, 2015, 53(6): 447-455.
Partridge MR, Dal Negro RW, Olivieri D. Understanding patients with asthma and COPD: insights from a European study. Prim Care Respir J, 2011, 20 (3): 315-323.
Centers for Disease Control and Prevention. Asthma/Data and Surveillance/Tables and Graphs Accessed 5 September 2014.
Eisner M, Yellin E, Trupin L, Blanc P. Asthma and smoking status in a population-based study of California adults. Public Health Reports, 2001, 116: 48-157.
Schayck O, Haughney J, Aubier M et al. Do asthmatic smokers benefit as much as nonsmokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study. Respiratory Medicine, 2012, 106: 189-196.
Pilcker J, Patel M, Reddel H. Effect of smoking status on the efficacy of the SMART regimen in high risk asthma. Respirology, 2016, 21: 858-866.